Olanzapine Long-Term Side Effects You Should Know About

Olanzapine is one of the most effective antipsychotics available for schizophrenia and bipolar disorder, but it also carries some of the most significant long-term side effects in its drug class. Weight gain, metabolic disruption, and shifts in cholesterol are the headline concerns, yet the picture extends further than most patients realize at the time of their first prescription. Understanding the full scope of these risks, and what can be done to reduce them, puts you in a better position to work with your prescriber on a plan that accounts for both psychiatric stability and physical health.

Why Olanzapine Causes Weight Gain

The weight gain associated with olanzapine is not simply about eating more. The drug interferes with several brain signaling systems that regulate appetite and metabolism simultaneously. One of the most studied pathways involves the serotonin 2C receptor. Olanzapine blocks this receptor, which normally helps signal satiety after eating. In animal studies, mice lacking the serotonin 2C receptor entirely did not gain as much weight on olanzapine, and treating olanzapine-fed mice with a drug that activates this receptor suppressed both overeating and weight gain while also improving glucose tolerance.¹

That is only one piece of the puzzle. Olanzapine also has a strong affinity for histamine H1 receptors in the brain. Meta-analyses have found a strong correlation between an antipsychotic’s tendency to bind the H1 receptor and its likelihood of causing weight gain, and olanzapine sits near the top of that list alongside clozapine.² Additionally, olanzapine affects muscarinic M3 receptors in brain regions that control food intake and insulin secretion, creating changes in hunger hormones like ghrelin and in insulin levels themselves.³ The result is a drug that simultaneously increases appetite, disrupts the hormonal signals that tell you to stop eating, and impairs the way your body handles the extra calories.

Metabolic Disruption Beyond the Scale

Weight gain is the most visible metabolic effect, but olanzapine also appears to impair blood sugar regulation through a mechanism that is partly independent of weight. Research on pancreatic beta cells, the cells that produce insulin, shows that olanzapine triggers stress within a cellular structure called the endoplasmic reticulum. When this happens, the cells become less able to secrete insulin in response to rising blood sugar. In laboratory studies, blocking this stress response restored normal insulin secretion even while olanzapine was still present.⁴ This means that even before a person has gained a significant amount of weight, olanzapine may already be nudging blood sugar in the wrong direction.

For people who stay on olanzapine for months or years, this combination of increased appetite, higher body weight, and impaired insulin function creates a significantly elevated risk for type 2 diabetes. Clinicians typically recommend monitoring fasting glucose and hemoglobin A1c regularly, though as we will see later, actual monitoring rates in practice fall well short of guidelines.

What Happens to Your Cholesterol

Olanzapine reliably worsens lipid profiles. A meta-analysis of randomized controlled trials found that olanzapine significantly increased triglycerides by about 25 mg/dL, total cholesterol by roughly 7 mg/dL, and LDL cholesterol by about 4 mg/dL, while HDL cholesterol showed no meaningful change.⁵ A separate meta-analysis of studies tracking patients from baseline through treatment found similar patterns: triglycerides and total cholesterol rose consistently, with LDL also climbing, and HDL remaining essentially flat.⁶

The triglyceride increase is the most striking component. A study comparing patients on olanzapine with those on no antipsychotic or on older-generation drugs found that olanzapine was associated with nearly a five-fold increase in the odds of developing hyperlipidemia compared with no antipsychotic use, and more than a three-fold increase compared with conventional antipsychotics.⁷ These lipid changes matter because elevated triglycerides and LDL are established risk factors for cardiovascular disease over the long term. One important detail from the dose-response meta-analysis: lipid changes were more pronounced at doses of 10 mg per day or above and in individuals who started treatment at a normal weight, suggesting that people who are lean at the outset are not protected and may actually see sharper shifts.⁵

Tardive Dyskinesia and Movement Disorders

Tardive dyskinesia, the involuntary repetitive movements that can develop after long-term use of drugs that block dopamine, is less common with olanzapine than with older antipsychotics. A large randomized trial comparing olanzapine with haloperidol found the one-year risk was about 0.5% with olanzapine versus roughly 7.5% with haloperidol, making olanzapine’s risk dramatically lower.⁸ Still, “lower” does not mean zero. In a two-year study of elderly patients who had never taken antipsychotics before, the cumulative tardive dyskinesia rate with olanzapine reached about 11% by the end of the second year.⁹ Older age and longer treatment are the two biggest risk factors, so this is worth monitoring even though the drug is considered one of the safer options for movement side effects.

Brain Structure Changes

A more unsettling area of research involves what olanzapine may do to brain tissue over time. A study of patients with major depressive disorder and psychotic features found that those taking olanzapine, compared with placebo, showed significant decreases in cortical thickness in both brain hemispheres, even when the analysis was restricted to people who had achieved and maintained remission from their psychiatric symptoms.¹⁰ Animal research has pointed in the same direction: chronic olanzapine exposure in rats led to decreased cortex volume.¹¹

These findings are concerning but need context. Schizophrenia and related psychotic disorders themselves are associated with progressive brain volume changes, and separating the drug’s effect from the illness’s effect is genuinely difficult. The human study cited above used patients with depression rather than schizophrenia, which helps isolate the drug effect, but it involved a relatively short treatment window. Whether these cortical thinning changes translate into functional problems, and how they interact with the underlying illness over years, remains an open question that researchers continue to investigate.

Cognitive and Anticholinergic Effects

Olanzapine has meaningful anticholinergic activity, meaning it blocks acetylcholine, a neurotransmitter involved in memory and attention. A meta-analysis examining the relationship between anticholinergic burden and cognition in people with psychotic disorders found a consistent negative association across multiple cognitive domains. Higher anticholinergic burden was linked to worse performance on tests of global cognition, verbal learning, working memory, processing speed, and attention.¹² When anticholinergic medications were tapered off, scores in verbal learning, working memory, and executive functions improved.¹²

This matters because cognitive difficulties are already a core feature of schizophrenia, and patients often report that “fuzzy thinking” is among the most distressing parts of their experience. A study of chronic schizophrenia patients confirmed that higher anticholinergic drug scores and higher overall antipsychotic doses were both independently associated with lower cognitive performance.¹³ If you are taking olanzapine alongside other medications with anticholinergic properties, such as certain bladder medications, antihistamines, or tricyclic antidepressants, the cognitive burden can stack up. Raising this with your prescriber is worthwhile, because reducing total anticholinergic load is one of the most actionable steps for protecting cognition.

Liver Health

Olanzapine has been linked to the development of fatty liver disease in both animal models and laboratory cell studies. In rodent experiments, eight weeks of treatment produced clear hepatic steatosis, or fat accumulation in the liver, in a dose-dependent manner, and this occurred regardless of whether the animals were on a high-fat or normal diet.¹⁴ Olanzapine treatment also raised blood markers of liver damage, specifically ALT and AST, in animal models.¹⁵

The human evidence for olanzapine-induced fatty liver is less direct. Most of the controlled data comes from animal studies and cell models, and human cases tend to be reported as individual case studies or inferred from the metabolic syndrome olanzapine creates. The practical takeaway is that if you already have risk factors for fatty liver disease, including obesity, diabetes, or heavy alcohol use, long-term olanzapine use adds another layer of concern. Periodic liver function tests are reasonable, though they are not always part of standard monitoring protocols.

Bone Density

People with schizophrenia have higher rates of osteoporosis than the general population, and it is natural to wonder whether antipsychotics contribute. Some antipsychotics, particularly those that raise prolactin levels, are associated with bone mineral density loss. Olanzapine, however, raises prolactin much less than drugs like risperidone. A study comparing the two found that risperidone-treated patients had significantly higher prolactin levels and lower bone density measurements than those on olanzapine.¹⁶ A larger study concluded that schizophrenia itself, rather than long-term olanzapine use, was the more important correlate of bone loss.¹⁷ So while bone health matters for anyone on long-term psychiatric medication, olanzapine is not the main culprit here.

Olanzapine in Older Adults with Dementia

Antipsychotics are sometimes prescribed off-label to manage agitation or psychosis in people with dementia, and this is an area where olanzapine’s risks become particularly serious. A clinical cohort study found that patients with dementia who were prescribed olanzapine had a roughly 32% higher risk of death compared with those not on antipsychotics.¹⁸ Risperidone showed a similar elevated risk. Literature reviews have also raised concerns about an increased risk of strokes and other cerebrovascular events in this population.¹⁹ All atypical antipsychotics carry a black-box warning from the FDA regarding increased mortality in elderly patients with dementia-related psychosis. If a family member with dementia is prescribed olanzapine, this risk deserves a frank conversation with the treating physician about whether non-pharmacological alternatives have been exhausted.

What Happens When You Stop

Discontinuing olanzapine, especially abruptly, can produce its own set of problems. A review of the literature found evidence for a phenomenon sometimes called supersensitivity psychosis, where stopping an antipsychotic triggers a rapid-onset psychotic episode that may be a feature of drug withdrawal rather than simply the return of the underlying illness.²⁰ Case reports have documented both supersensitivity psychosis and withdrawal-emergent dyskinesia, a movement disorder that appears after discontinuation, specifically with olanzapine.²¹

The practical lesson is that tapering slowly under medical supervision is critical. Stopping olanzapine cold turkey is risky, and even planned tapers can be bumpy. If you and your prescriber decide to discontinue or switch medications, expect the process to take weeks or months, not days.

Strategies That Help Manage the Side Effects

The most studied pharmacological countermeasure for olanzapine-induced weight gain is metformin, a diabetes drug. A systematic review and meta-analysis found that patients taking metformin alongside olanzapine weighed about 5 kg less than those on placebo after 12 weeks.²² A trial in first-episode patients who had never taken antipsychotics before found that adding metformin from the start reduced weight gain, prevented the rise in insulin resistance that the placebo group experienced, and resulted in fewer patients crossing the threshold of clinically meaningful weight gain.²³ However, not all trials have shown such clear benefits. One study found metformin did not fully prevent olanzapine-induced weight gain, though insulin resistance markers did improve.²⁴ On balance, the evidence leans toward metformin providing modest but real help, especially if started early.

A newer option is a combination tablet that pairs olanzapine with samidorphan, an opioid receptor antagonist designed specifically to blunt weight gain while preserving olanzapine’s psychiatric benefits. In pooled data from clinical trials, patients on the combination gained about 2.6 kg at 12 weeks compared with about 4 kg on olanzapine alone, and weight gain with the combination tended to level off after the first month while it continued climbing on olanzapine alone.²⁵ Fewer patients on the combination crossed the threshold of gaining 7% or more of their body weight. The combination was approved by the FDA for schizophrenia and bipolar I disorder.²⁶ It does not eliminate weight gain entirely, but the difference is clinically meaningful for many patients.

The Monitoring Gap

Guidelines recommend regular monitoring of weight, blood sugar, and lipids for anyone on a second-generation antipsychotic. In practice, this happens far less often than it should. A study of children and adolescents on these medications found that full guideline-recommended monitoring of BMI occurred in fewer than 5% of patients, full glucose monitoring in about 6.5%, and full cholesterol monitoring in under 1%.²⁷ The picture in adults is not much better. A study of commercially insured adults found that baseline lipid testing occurred in only about 10% of patients starting a second-generation antipsychotic, and 12-week testing rates were even lower.²⁸

This means that you cannot assume your metabolic health is being tracked adequately just because you are seeing a prescriber regularly. Ask specifically about fasting glucose, lipid panels, and weight tracking. If your psychiatrist does not order these tests, your primary care doctor can. The side effects of olanzapine develop gradually enough that catching problems early, before full-blown diabetes or severe dyslipidemia sets in, makes a real difference in outcomes.

Who Is Genetically More Vulnerable

Not everyone on olanzapine gains the same amount of weight, and genetics explain part of the variation. The most consistently replicated genetic findings involve variations in the serotonin 2C receptor gene and the leptin gene. Variations in other genes, including FTO (the “fat gene” that also influences obesity risk in the general population) and the melanocortin-4 receptor gene, have also been linked to greater susceptibility to antipsychotic weight gain.²⁹ Pharmacogenomic testing for these variants is not yet a routine part of prescribing in most settings, but it is an area that could eventually help predict who will be most affected and guide medication choices earlier in treatment.

Sleep, Sedation, and Nighttime Disruptions

Olanzapine is one of the more sedating antipsychotics, and many patients experience improved sleep initially, including increases in total sleep time and sleep efficiency. It also increases slow-wave sleep, the deep restorative phase, in both healthy volunteers and people with schizophrenia.³⁰ For people whose psychiatric illness has destroyed their sleep, this can feel like a genuine benefit. Over the long term, though, the sedation can bleed into daytime drowsiness, and specific sleep disorders including restless legs syndrome, sleep-related breathing problems, night-eating syndrome, and even sleepwalking have been described as possible adverse effects of antipsychotics and should be considered if sleep quality deteriorates despite the medication.³⁰

How Patients Describe Life on Olanzapine

Clinical trials measure lab values and symptom scores, but they sometimes underrepresent the subjective experience of taking a medication for years. A cross-sectional survey comparing patients on olanzapine with those on risperidone found that olanzapine-treated patients were more likely to report reduced social and family interaction, less participation in recreational activities, greater difficulty thinking clearly, and more feelings of uselessness and isolation.³¹ Weight gain and sedation were likely contributors to many of these complaints. The study is a useful reminder that side effects are not just numbers on a lab report. They reshape daily life, relationships, and self-image in ways that can erode treatment adherence if they go unaddressed.

Olanzapine During Pregnancy

For women who become pregnant while taking olanzapine, data from a global safety surveillance review is somewhat reassuring. Among 610 pregnancies with known outcomes, about 66% resulted in normal births, roughly 10% in premature births, about 9% in spontaneous abortions, and about 4% in congenital anomalies. The rates of spontaneous abortion, stillbirth, premature birth, and congenital anomalies did not appear elevated compared with general population background rates.³² This does not mean olanzapine is without risk in pregnancy. The metabolic effects, particularly weight gain and blood sugar disruption, can compound the metabolic changes that pregnancy itself causes. Decisions about continuing olanzapine during pregnancy involve weighing the risk of untreated psychosis against these concerns, and they should be made with a psychiatrist and obstetrician working together.

Rare but Serious Reactions

Beyond the gradual metabolic and neurological effects, olanzapine can in rare cases trigger acute systemic reactions. One such reaction is DRESS syndrome, which stands for drug reaction with eosinophilia and systemic symptoms. It typically starts with a skin rash and blood abnormalities and can progress to involvement of internal organs, including the liver and kidneys, if the drug is not stopped promptly.³³ DRESS is very uncommon, but because it can become life-threatening, any unexplained rash that develops after starting or adjusting olanzapine warrants prompt medical evaluation.